Sorin Group S.p.A.: CLEAR Study Demonstrates Automatic Optimization of CRT with SonR Improves Heart Failure Patients Response Rates

PARIS--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters Code: SORIN.MI), a global leader in the treatment of cardiovascular diseases, announced today that the CLEAR study has met its primary endpoint.